{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:56:30Z","timestamp":1791618990099,"version":"4.3.4"},"reference-count":175,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Cancer treatment-induced thrombocytopenia (CTIT) is a common adverse effect in malignant tumor patients, significantly increasing the risk of bleeding and negatively impacting treatment efficacy and quality of life. Current treatment options for CTIT primarily include platelet transfusion, recombinant human interleukin-11 (rhIL-11), recombinant human thrombopoietin (rhTPO) and thrombopoietin receptor agonists (TPO-RAs). However, these methods have their limitations; for instance, platelet transfusions may cause adverse reactions, and the efficacy and safety of rhTPO and TPO-RAs remain controversial. This review aims to summarize the current treatment landscape for CTIT and explore new therapeutic advancement, including the potential role of traditional Chinese medicine, in order to provide more effective treatment strategies for clinical practice.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1634688","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T05:33:02Z","timestamp":1758605582000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Cancer treatment-induced thrombocytopenia: diagnosis, mechanisms and management"],"prefix":"10.3389","volume":"16","author":[{"given":"Xutong","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaofeng","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghao","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2165\/11594310-000000000-00000","article-title":"Thrombocytopenia in adult cancer patients receiving cytotoxic chemotherapy: results from a retrospective hospital-based cohort study","volume":"34","author":"Ten Berg","year":"2011","journal-title":"Drug Saf"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.11.020","article-title":"Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007","volume":"31","author":"Wu","year":"2009","journal-title":"Clin Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201304054","article-title":"The incredible journey: From megakaryocyte development to platelet formation","volume":"201","author":"Machlus","year":"2013","journal-title":"J Cell Biol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12885-019-5354-5","article-title":"Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice","volume":"19","author":"Weycker","year":"2019","journal-title":"BMC Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05466-1","article-title":"Bleeding risk assessment in immune thrombocytopenia","volume":"102","author":"Mishra","year":"2023","journal-title":"Ann Hematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s1040-8428(01)00182-2","article-title":"What is the proper threshold for platelet transfusion in patients with chemotherapy-induced thrombocytopenia","volume":"42","author":"Benjamin","year":"2002","journal-title":"Crit Rev Oncol Hematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1697930","article-title":"Drug-induced thrombocytopenia: mechanisms and laboratory diagnostics","volume":"46","author":"Danese","year":"2020","journal-title":"Semin Thromb Hemost"},{"key":"B8","doi-asserted-by":"publisher","first-page":"113666","DOI":"10.1016\/j.jpeds.2023.113666","article-title":"Neonatal thrombocytopenia: factors associated with the platelet count increment following platelet transfusion","volume":"263","author":"Christensen","year":"2023","journal-title":"J Pediatr"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.5414\/CP204367","article-title":"Factors associated with thrombocytopenia in patients treated with pegfilgrastim","volume":"61","author":"Nishimura","year":"2023","journal-title":"Int J Clin Pharmacol Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1055\/a-0962-6361","article-title":"Acquired immune thrombocytopenia: An update on aspects of diagnosis and management relevant for intensive care medicine","volume":"145","author":"Hidiatov","year":"2020","journal-title":"Dtsch Med Wochenschr"},{"key":"B11","doi-asserted-by":"publisher","first-page":"4438","DOI":"10.3390\/ijms24054438","article-title":"Novel biomarkers for diagnosis and monitoring of immune thrombocytopenia","volume":"24","author":"Allegra","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1568243","article-title":"Predictive factors for persistent thrombocytopenia after peptide receptor radioligand therapy in enteropancreatic neuroendocrine tumors","volume":"16","author":"Ferrara","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e29776","DOI":"10.1002\/pbc.29776","article-title":"Chemotherapy-induced thrombocytopenia in pediatric oncology: Scope of the problem and opportunities for intervention","volume":"69","author":"Degliuomini","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13595","article-title":"The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic Malignancies","volume":"106","author":"Shaw","year":"2021","journal-title":"Eur J Haematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: A systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.9007","article-title":"randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group","volume":"27","author":"Poplin","year":"2009","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl377","article-title":"Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan","volume":"18","author":"Ohe","year":"2007","journal-title":"Ann Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604536","article-title":"A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer","volume":"99","author":"Lee","year":"2008","journal-title":"Br J Cancer"},{"key":"B21","article-title":"Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors","volume":"80","author":"Budd","year":"1997","journal-title":"Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.01.011","article-title":"Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial","volume":"48","author":"Gross-Goupil","year":"2012","journal-title":"Eur J Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.9114","article-title":"Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer","volume":"27","author":"Gr\u00f8nberg","year":"2009","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603810","article-title":"Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702","volume":"97","author":"Okamoto","year":"2007","journal-title":"Br J Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.058","article-title":"Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer","volume":"21","author":"Fuchs","year":"2003","journal-title":"J Clin Oncol"},{"key":"B26","article-title":"A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma","volume":"85","author":"Rothenberg","year":"1999","journal-title":"Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-532341","article-title":"Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study","volume":"123","author":"Shah","year":"2014","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17098-0","article-title":"Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial","volume":"364","author":"Verweij","year":"2004","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.7855","article-title":"Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial","volume":"319","author":"Li","year":"2018","journal-title":"JAMA"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1680","article-title":"A single-arm, multicenter, phase II study of camrelizumab in relapsed or refractory classical hodgkin lymphoma","volume":"25","author":"Song","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3922","article-title":"Safety, efficacy, and biomarker analysis of toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial","volume":"26","author":"Tang","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.10.3457","article-title":"Recombinant human thrombopoietin: basic biology and evaluation of clinical studies","volume":"100","author":"Kuter","year":"2002","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2015.0166","article-title":"Dose delays, dose reductions, and relative dose intensity in patients with cancer who received adjuvant or neoadjuvant chemotherapy in community oncology practices","volume":"13","author":"Denduluri","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study","volume":"6","author":"Delanoy","year":"2019","journal-title":"Lancet Haematol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009016","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"139","author":"Kroll","year":"2022","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02630-w","article-title":"Risk and adverse clinical outcomes of thrombocytopenia among patients with solid tumors-a Danish population-based cohort study","volume":"130","author":"Adelborg","year":"2024","journal-title":"Br J Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219861423","article-title":"Predicting chemotherapy-induced thrombocytopenia in cancer patients with solid tumors or lymphoma","volume":"26","author":"Razzaghdoust","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"B39","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1038\/s41598-023-27824-9","article-title":"The predictive model for risk of chemotherapy-induced thrombocytopenia based on antineoplastic drugs for solid tumors in eastern China","volume":"13","author":"Zhou","year":"2023","journal-title":"Sci Rep"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6062","article-title":"Incidence, consequences, and predictors of serious chemotherapy-induced thrombocytopenia in nasopharyngeal carcinoma","volume":"12","author":"Zhang","year":"2023","journal-title":"Cancer Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.7.2303","article-title":"Radiotherapy-associated neutropenia and thrombocytopenia: analysis of risk factors and development of a predictive model","volume":"89","author":"Mac","year":"1997","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","first-page":"153880","DOI":"10.1016\/j.phymed.2021.153880","article-title":"Proanthocyanidin A1 promotes the production of platelets to ameliorate chemotherapy-induced thrombocytopenia through activating JAK2\/STAT3 pathway","volume":"95","author":"Wang","year":"2022","journal-title":"Phytomedicine"},{"key":"B43","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s12672-023-00616-3","article-title":"Chemotherapy-induced thrombocytopenia: literature review","volume":"14","author":"Gao","year":"2023","journal-title":"Discov Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2020.07.007","article-title":"Oxaliplatin-induced immune thrombocytopenia: A case report and literature review","volume":"20","author":"Stack","year":"2021","journal-title":"Clin Colorectal Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e9929","DOI":"10.7759\/cureus.9929","article-title":"Oxaliplatin-induced thrombocytopenia: A case report and review of pathophysiology of various speculative mechanisms","volume":"12","author":"Ghazanfar","year":"2020","journal-title":"Cureus"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds074","article-title":"Oxaliplatin-related thrombocytopenia","volume":"23","author":"Jardim","year":"2012","journal-title":"Ann Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-007-0675-5","article-title":"Oxaliplatin-induced immune mediated thrombocytopenia","volume":"62","author":"Beg","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3181c79403","article-title":"Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome","volume":"251","author":"Soubrane","year":"2010","journal-title":"Ann Surg"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.5701","article-title":"Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury","volume":"28","author":"Overman","year":"2010","journal-title":"J Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.lungcan.2019.07.010","article-title":"Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis","volume":"135","author":"Griesinger","year":"2019","journal-title":"Lung Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00795","article-title":"Gemcitabine and paclitaxel versus gemcitabine alone after 5-fluorouracil, oxaliplatin, and irinotecan in metastatic pancreatic adenocarcinoma: A randomized phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER study","volume":"42","author":"De La Fouchardi\u00e8re","year":"2024","journal-title":"J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/jhbp.1219","article-title":"Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA)","volume":"30","author":"Ioka","year":"2023","journal-title":"J Hepatobil Pancreat Sci"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-012-1822-1","article-title":"Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study)","volume":"69","author":"Ozaka","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2008.40.1.22","article-title":"Gemcitabine versus gemcitabine combined with cisplatin treatment locally advanced or metastatic pancreatic cancer: a retrospective analysis","volume":"40","author":"Choi","year":"2008","journal-title":"Cancer Res Treat"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70203-6","article-title":"Gemcitabine-associated thrombotic thrombocytopenic purpura","volume":"8","author":"Zupancic","year":"2007","journal-title":"Lancet Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"101205","DOI":"10.1016\/j.mam.2023.101205","article-title":"Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming","volume":"93","author":"Mattioli","year":"2023","journal-title":"Mol Aspects Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-020-10063-9","article-title":"Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets","volume":"26","author":"Fabiani","year":"2021","journal-title":"Heart Fail Rev"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2020.790","article-title":"The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: A pooled analysis of 23 clinical trials and 8,436 patients","volume":"53","author":"Tang","year":"2021","journal-title":"Cancer Res Treat"},{"key":"B60","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1186\/s12885-019-5701-6","article-title":"Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis","volume":"19","author":"Sun","year":"2019","journal-title":"BMC Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0419","article-title":"Safety and tolerability of PD-1\/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: A meta-analysis","volume":"22","author":"Nishijima","year":"2017","journal-title":"Oncologist"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00333-8","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis","volume":"22","author":"Zhou","year":"2021","journal-title":"Lancet Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1398667","article-title":"Immune-related adverse events in small-cell lung cancer patients treated with immune checkpoint inhibitors: a comprehensive analysis from the FDA adverse event reporting system","volume":"15","author":"Bai","year":"2024","journal-title":"Front Pharmacol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1810479","article-title":"Immune thrombocytopenia","volume":"381","author":"Cooper","year":"2019","journal-title":"N Engl J Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.01.013","article-title":"Hematological immune related adverse events after treatment with immune checkpoint inhibitors","volume":"147","author":"Kramer","year":"2021","journal-title":"Eur J Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03068-2","article-title":"Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival","volume":"71","author":"Haddad","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3779\/j.issn.1009-3419","article-title":"Immune thrombocytopenia induced by sintilimab in lung cancer: A case report and literature review","volume":"26","author":"Cai","year":"2023","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"B68","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40425-017-0210-0","article-title":"Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy","volume":"5","author":"Shiuan","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B69","doi-asserted-by":"publisher","first-page":"111606","DOI":"10.1016\/j.intimp.2024.111606","article-title":"PD-1\/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review","volume":"129","author":"Moore","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.10.5151","article-title":"Electromagnetic navigation system for CT-guided biopsy of small lesions","volume":"196","author":"Appelbaum","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.670391","article-title":"The role of cytokines in predicting the response and adverse events related to immune checkpoint inhibitors","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005841","article-title":"Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature","volume":"11","author":"Liu","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B73","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.it.2021.02.006","article-title":"and preventing immune checkpoint inhibitor toxicity: targeting cytokines","volume":"42","author":"Kang","year":"2021","journal-title":"Trends Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for immune-related adverse events: A practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front Immunol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2217\/imt-2017-0100","article-title":"Immune-mediated thrombocytopenia and hypothyroidism in a lung cancer patient treated with nivolumab","volume":"10","author":"Jotatsu","year":"2018","journal-title":"Immunotherapy"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1159\/000477968","article-title":"Immune thrombocytopenia induced by nivolumab in a metastatic non-small cell lung cancer patient","volume":"40","author":"Karakas","year":"2017","journal-title":"Oncol Res Treat"},{"key":"B77","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13052-021-01131-3","article-title":"IL-23\/Th17 pathway and IL-17A gene polymorphism in Egyptian children with immune thrombocbytopenic purpura","volume":"47","author":"Ismail","year":"2021","journal-title":"Ital J Pediatr"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-023-05242-3","article-title":"Contribution of T helper 17 cells and interleukin-17 to the pathogenesis of primary immune thrombocytopenia in Egyptian children","volume":"182","author":"Hassan","year":"2023","journal-title":"Eur J Pediatr"},{"key":"B79","doi-asserted-by":"publisher","first-page":"176548","DOI":"10.1016\/j.ejphar.2024.176548","article-title":"Alnustone promotes megakaryocyte differentiation and platelet production via the interleukin-17A\/interleukin-17A receptor\/Src\/RAC1\/MEK\/ERK signaling pathway","volume":"971","author":"Li","year":"2024","journal-title":"Eur J Pharmacol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"15337","DOI":"10.1038\/s41598-020-72275-1","article-title":"Predicting bleeding risk in a Chinese immune thrombocytopenia (ITP) population: development and assessment of a new predictive nomogram","volume":"10","author":"Wang","year":"2020","journal-title":"Sci Rep"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3109\/09537104.2014.934217","article-title":"Elevated expression of IL-12 and IL-23 in patients with primary immune thrombocytopenia","volume":"26","author":"Li","year":"2015","journal-title":"Platelets"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223885","article-title":"Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis","volume":"82","author":"Bass","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"7005","DOI":"10.1038\/s41467-021-27303-7","article-title":"Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer","volume":"12","author":"Hinterleitner","year":"2021","journal-title":"Nat Commun"},{"key":"B85","doi-asserted-by":"publisher","first-page":"115709","DOI":"10.1016\/j.biopha.2023.115709","article-title":"High levels of PD-L1 on platelets of NSCLC patients contributes to the pharmacological activity of Atezolizumab","volume":"168","author":"Colarusso","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00714-6","article-title":"Towards targeting the breast cancer immune microenvironment","volume":"24","author":"Harris","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13349","article-title":"Haematologic toxicities with PARP inhibitors in cancer patients: an up-to-date meta-analysis of 29 randomized controlled trials","volume":"46","author":"Wang","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad185","article-title":"Thrombopoietin receptor agonists for thrombocytopenia secondary to HER2-targeted antibody drug conjugates","volume":"28","author":"Rainone","year":"2023","journal-title":"Oncologist"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1269922","article-title":"The adverse events of CDK4\/6 inhibitors for HR+\/HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials","volume":"15","author":"Pu","year":"2024","journal-title":"Front Pharmacol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.3390\/ph16101340","article-title":"Hematological events potentially associated with CDK4\/6 inhibitors: an analysis from the european spontaneous adverse event reporting system","volume":"16","author":"Martins","year":"2023","journal-title":"Pharm (Basel)"},{"key":"B91","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/medsci9020042","article-title":"CDK4\/6 inhibitors and arthralgia: A single institution experience","volume":"9","author":"Andrikopoulou","year":"2021","journal-title":"Med Sci (Basel)"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00376-4","article-title":"Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial","volume":"22","author":"de Bono","year":"2021","journal-title":"Lancet Oncol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"4904","DOI":"10.3390\/cancers15194904","article-title":"Hematological toxicities with PARP inhibitors in prostate cancer: A systematic review and meta-analysis of phase II\/III randomized controlled trials","volume":"15","author":"Bowling","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-022-01167-6","article-title":"Pharmacokinetics and pharmacodynamics of PARP inhibitors in oncology","volume":"61","author":"Bruin","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c00185","article-title":"Discovery and pharmacological evaluation of potent and highly selective PARP1 inhibitors","volume":"68","author":"Guo","year":"2025","journal-title":"J Med Chem"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02326-7","article-title":"PARP inhibitors: enhancing efficacy through rational combinations","volume":"129","author":"Bhamidipati","year":"2023","journal-title":"Br J Cancer"},{"key":"B99","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40360-024-00770-6","article-title":"Comparative analysis of adverse events associated with CDK4\/6 inhibitors based on FDA\u2019s adverse event reporting system: a case control pharmacovigilance study","volume":"25","author":"Lin","year":"2024","journal-title":"BMC Pharmacol Toxicol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1279","article-title":"Phase 1 combination study of the CHK1 inhibitor prexasertib and the PARP inhibitor olaparib in high-grade serous ovarian cancer and other solid tumors","volume":"27","author":"Do","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad127","article-title":"Novel anti-HER2 antibody-drug conjugates versus T-DM1 for HER2-positive metastatic breast cancer after tyrosine kinase inhibitors treatment","volume":"28","author":"Ji","year":"2023","journal-title":"Oncologist"},{"key":"B102","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s12282-023-01473-2","article-title":"HER2-targeted antibody-drug conjugates for breast cancer: ancestry and dose adjustment for thrombocytopenia","volume":"30","author":"Rainone","year":"2023","journal-title":"Breast Cancer"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S147726","article-title":"Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials","volume":"11","author":"Zhou","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"B104","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0710","article-title":"Inhibition of megakaryocyte differentiation by antibody-drug conjugates (ADCs) is mediated by macropinocytosis: implications for ADC-induced thrombocytopenia","volume":"16","author":"Zhao","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1678732","article-title":"Pathophysiology of autoimmune thrombocytopenia: current insight with a focus on thrombopoiesis","volume":"39","author":"Marini","year":"2019","journal-title":"Hamostaseologie"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002922","article-title":"A novel mechanism of thrombocytopenia by PS exposure through TMEM16F in sphingomyelin synthase 1 deficiency","volume":"5","author":"Fujii","year":"2021","journal-title":"Blood Adv"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2630","article-title":"Design and preclinical evaluation of a novel B7-H4-directed antibody-drug conjugate, AZD8205, alone and in combination with the PARP1-selective inhibitor AZD5305","volume":"29","author":"Kinneer","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.1734","article-title":"Platelet transfusion for patients with cancer: american society of clinical oncology clinical practice guideline update","volume":"36","author":"Schiffer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"101135","DOI":"10.1016\/j.blre.2023.101135","article-title":"Platelet transfusion refractoriness due to HLA alloimmunization: Evolving paradigms in mechanisms and management","volume":"62","author":"Panch","year":"2023","journal-title":"Blood Rev"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1125367","article-title":"Anti-HLA Class I alloantibodies in platelet transfusion refractoriness: From mechanisms and determinants to therapeutic prospects","volume":"14","author":"Couvidou","year":"2023","journal-title":"Front Immunol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-860809","article-title":"Transfusion-associated circulatory overload and transfusion-related acute lung injury","volume":"133","author":"Semple","year":"2019","journal-title":"Blood"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022593","article-title":"Platelet dysfunction reversal with cold-stored vs room temperature-stored platelet transfusions","volume":"143","author":"Kogler","year":"2024","journal-title":"Blood"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1111\/jep.13152","article-title":"Efficacy and safety of recombinant human interleukin-11 in the treatment of acute leukaemia patients with chemotherapy-induced thrombocytopenia: A systematic review and meta-analysis","volume":"26","author":"Liu","year":"2020","journal-title":"J Eval Clin Pract"},{"key":"B115","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cytogfr.2021.04.002","article-title":"The cytokine interleukin-11 crucially links bone formation, remodeling and resorption","volume":"60","author":"Kespohl","year":"2021","journal-title":"Cytokine Growth Factor Rev"},{"key":"B116","article-title":"Recombinant human interleukin-11 stimulates megakaryocytopoiesis and increases peripheral platelets in normal and splenectomized mice","volume":"81","author":"Neben","year":"1993","journal-title":"Blood"},{"key":"B117","article-title":"Recombinant human interleukin-11 directly promotes megakaryocytopoiesis in vitro","volume":"90","author":"Weich","year":"1997","journal-title":"Blood"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-041818-011649","article-title":"Hiding in plain sight: interleukin-11 emerges as a master regulator of fibrosis, tissue integrity, and stromal inflammation","volume":"71","author":"Cook","year":"2020","journal-title":"Annu Rev Med"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1288964","article-title":"Effectiveness and economic evaluation of rhTPO and rhIL-11 in the treatment of cancer therapy induced thrombocytopenia based on real-world research","volume":"15","author":"Gong","year":"2024","journal-title":"Front Pharmacol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.11.3368","article-title":"Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin","volume":"15","author":"Isaacs","year":"1997","journal-title":"J Clin Oncol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.9.3615.bloodjournal8793615","article-title":"A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy","volume":"87","author":"Gordon","year":"1996","journal-title":"Blood"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvae224","article-title":"Interleukin 11 therapy causes acute left ventricular dysfunction","volume":"120","author":"Sweeney","year":"2024","journal-title":"Cardiovasc Res"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401514","article-title":"Hematopoietic, immunomodulatory and epithelial effects of interleukin-11","volume":"13","author":"Schwertschlag","year":"1999","journal-title":"Leukemia"},{"key":"B124","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1146\/annurev.med.60.042307.181154","article-title":"Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia","volume":"60","author":"Kuter.","year":"2009","journal-title":"Annu Rev Med"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-132-5-200003070-00005","article-title":"Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer","volume":"132","author":"Vadhan-Raj","year":"2000","journal-title":"Ann Intern Med"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-126-9-199705010-00001","article-title":"Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer","volume":"126","author":"Vadhan-Raj","year":"1997","journal-title":"Ann Intern Med"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1459605","article-title":"Recombinant human thrombopoietin (rh-TPO) for the prevention of severe thrombocytopenia induced by high-dose cytarabine: a prospective, randomized, self-controlled study","volume":"59","author":"Wang","year":"2018","journal-title":"Leuk Lymph"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.003","article-title":"Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia","volume":"21","author":"Vadhan-Raj","year":"2003","journal-title":"J Clin Oncol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3760\/j:issn:0376-2491.2004.05.013","article-title":"The clinical study of recombinant human thrombopoietin in the treatment of chemotherapy-induced severe thrombocytopenia","volume":"84","author":"Bai","year":"2004","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17808","article-title":"A multicentre double-blind, double-dummy, randomised study of recombinant human thrombopoietin versus eltrombopag in the treatment of immune thrombocytopenia in Chinese adult patients","volume":"195","author":"Mei","year":"2021","journal-title":"Br J Haematol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35292","article-title":"A real-world observation on thrombopoietic agents for patients with cancer treatment-induced thrombocytopenia in China: A multicenter, cross-sectional study","volume":"130","author":"Chen","year":"2024","journal-title":"Cancer"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct1014202","article-title":"Thrombopoietin-receptor agonists for primary immune thrombocytopenia","volume":"365","author":"Imbach","year":"2011","journal-title":"N Engl J Med"},{"key":"B133","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1186\/s12885-023-10975-3","article-title":"Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia","volume":"23","author":"Shin","year":"2023","journal-title":"BMC Cancer"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.704093","article-title":"Comparative efficacy and safety of thrombopoietin receptor agonists in adults with thrombocytopenia: A systematic review and network meta-analysis of randomized controlled trial","volume":"12","author":"Deng","year":"2021","journal-title":"Front Pharmacol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"100909","DOI":"10.1016\/j.blre.2021.100909","article-title":"The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag","volume":"53","author":"Kuter","year":"2022","journal-title":"Blood Rev"},{"key":"B136","doi-asserted-by":"publisher","first-page":"6907","DOI":"10.3390\/ijms22136907","article-title":"Elucidating the mechanism of action of the attributed immunomodulatory role of eltrombopag in primary immune thrombocytopenia: an in silico approach","volume":"22","author":"Lozano","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1172\/JCI149856","article-title":"Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell\u00a0expansion in aplastic anemia","volume":"132","author":"Guan","year":"2022","journal-title":"J Clin Invest"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2319-9","article-title":"Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study","volume":"106","author":"Winer","year":"2017","journal-title":"Int J Hematol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.701539","article-title":"A real-world observation of eltrombopag and recombinant human thrombopoietin (rhTPO) in lymphoma patients with chemotherapy induced thrombocytopenia","volume":"11","author":"Zhu","year":"2021","journal-title":"Front Oncol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.4274\/tjh.galenos.2019.2018.0307","article-title":"A multi-center study on the efficacy of eltrombopag in management of refractory chronic immune thrombocytopenia: A real-life experience","volume":"36","author":"\u00c7ekdemir","year":"2019","journal-title":"Turk J Haematol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13809","article-title":"Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist","volume":"22","author":"Xie","year":"2018","journal-title":"J Cell Mol Med"},{"key":"B142","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-021-01047-9","article-title":"A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia","volume":"14","author":"Mei","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40164-023-00377-3","article-title":"Hetrombopag plus porcine ATG and cyclosporine for the treatment of aplastic anaemia: early outcomes of a prospective pilot study","volume":"12","author":"Yang","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15078","article-title":"First-in-patient study of hetrombopag in patients with chronic idiopathic thrombocytopenic purpura","volume":"18","author":"Wang","year":"2020","journal-title":"J Thromb Haemost"},{"key":"B145","doi-asserted-by":"publisher","first-page":"17588359241260985","DOI":"10.1177\/17588359241260985","article-title":"Hetrombopag for the management of chemotherapy-induced thrombocytopenia in patients with advanced solid tumors: a multicenter, randomized, double-blind, placebo-controlled, phase II study","volume":"16","author":"Qin","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"102231","DOI":"10.1016\/j.rpth.2023.102231","article-title":"Hetrombopag plus recombinant human thrombopoietin for chemotherapy-induced thrombocytopenia in patients with solid tumors","volume":"7","author":"Xia","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S299591","article-title":"A Review of Romiplostim Mechanism of Action and Clinical Applicability","volume":"15","author":"Bussel","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200969030-00006","article-title":"Romiplostim","volume":"69","author":"Frampton","year":"2009","journal-title":"Drugs"},{"key":"B149","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/09537104.2019.1624709","article-title":"Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP)","volume":"31","author":"Kapur","year":"2020","journal-title":"Platelets"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-281717","article-title":"Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents","volume":"116","author":"Bao","year":"2010","journal-title":"Blood"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01931","article-title":"Romiplostim treatment of chemotherapy-induced thrombocytopenia","volume":"37","author":"Soff","year":"2019","journal-title":"J Clin Oncol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.251900","article-title":"A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic Malignancies","volume":"106","author":"Al-Samkari","year":"2021","journal-title":"Haematologica"},{"key":"B153","doi-asserted-by":"publisher","first-page":"e7429","DOI":"10.1002\/cam4.7429","article-title":"Romiplostim in chemotherapy-induced thrombocytopenia: A review of the literature","volume":"13","author":"Soff","year":"2024","journal-title":"Cancer Med"},{"key":"B154","doi-asserted-by":"publisher","first-page":"2040620719837906","DOI":"10.1177\/2040620719837906","article-title":"Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia","volume":"10","author":"Gonz\u00e1lez-Porras","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"B155","doi-asserted-by":"publisher","first-page":"e41449","DOI":"10.1097\/MD.0000000000041449","article-title":"Refractory immune thrombocytopenia treated with low-dose decitabine combined with recombinant human thrombopoietin or eltrombopag: Two case reports","volume":"104","author":"Jiang","year":"2025","journal-title":"Med (Baltimore)"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0525-4","article-title":"Lusutrombopag: first global approval","volume":"76","author":"Kim","year":"2016","journal-title":"Drugs"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.11.047","article-title":"Lusutrombopag reduces need for platelet transfusion in patients with thrombocytopenia undergoing invasive procedures","volume":"17","author":"Hidaka","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13305","article-title":"Efficacy and safety of repeated use of lusutrombopag prior to radiofrequency ablation in patients with recurrent hepatocellular carcinoma and thrombocytopenia","volume":"49","author":"Ishikawa","year":"2019","journal-title":"Hepatol Res"},{"key":"B159","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1016\/j.cgh.2020.03.032","article-title":"Lusutrombopag is safe and efficacious for treatment of thrombocytopenia in patients with and without hepatocellular carcinoma","volume":"18","author":"Alkhouri","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2008.01198.x","article-title":"AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist","volume":"82","author":"Fukushima-Shintani","year":"2009","journal-title":"Eur J Haematol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01613-y","article-title":"Avatrombopag: A review in thrombocytopenia","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00001-1","article-title":"Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological Malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Al-Samkari","year":"2022","journal-title":"Lancet Haematol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12957-025-03659-8","article-title":"Observation on the efficacy of TPO receptor agonists and platelet transfusion in chemotherapy-induced thrombocytopenia in Malignant tumors","volume":"23","author":"Hu","year":"2025","journal-title":"World J Surg Oncol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"114745","DOI":"10.1016\/j.ejmech.2022.114745","article-title":"Hybrid molecules based on caffeic acid as potential therapeutics: A focused review","volume":"243","author":"Zhao","year":"2022","journal-title":"Eur J Med Chem"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jafc.2c03009","article-title":"Caffeic acid, an active ingredient in coffee, combines with DOX for multitarget combination therapy of lung cancer","volume":"70","author":"Bai","year":"2022","journal-title":"J Agric Food Chem"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.2174\/0113892010309341240517071344","article-title":"Revealing the curative possibilities: A comprehensive exploration of caffeic acid","author":"Goyal","year":"2024","journal-title":"Curr Pharm Biotechnol"},{"key":"B167","doi-asserted-by":"publisher","first-page":"e35353","DOI":"10.1097\/MD.0000000000035353","article-title":"Efficacy and safety of caffeic acid tablets in the treatment of thrombocytopenia: A systematic review and meta-analysis","volume":"102","author":"Yu","year":"2023","journal-title":"Med (Baltimore)"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1096\/fj.04-2126com","article-title":"Novel and therapeutic effect of caffeic acid and caffeic acid phenyl ester on hepatocarcinoma cells: complete regression of hepatoma growth and metastasis by dual mechanism","volume":"18","author":"Chung","year":"2004","journal-title":"FASEB J"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1748","article-title":"Caffeine and caffeic acid inhibit growth and modify estrogen receptor and insulin-like growth factor I receptor levels in human breast cancer","volume":"21","author":"Rosendahl","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl465","article-title":"A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity","volume":"18","author":"Mok","year":"2007","journal-title":"Ann Oncol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00252","article-title":"Ancient chinese medicine herbal formula huanglian jiedu decoction as a neoadjuvant treatment of chemotherapy by improving diarrhea and tumor response","volume":"11","author":"Chan","year":"2020","journal-title":"Front Pharmacol"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1007\/s11655-023-3558-7","article-title":"Chinese medicine combined with adjuvant chemotherapy for improving myelosuppression in colorectal cancer patients: A systematic review and network meta-analysis","volume":"30","author":"Li","year":"2024","journal-title":"Chin J Integr Med"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.609705","article-title":"Research status and molecular mechanism of the traditional chinese medicine and antitumor therapy combined strategy based on tumor microenvironment","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4896","article-title":"Traditional Chinese medicines and capecitabine-based chemotherapy for colorectal cancer treatment: A meta-analysis","volume":"12","author":"Jiang","year":"2023","journal-title":"Cancer Med"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-04892-y","article-title":"Network meta-analysis of 8 types of traditional Chinese medicine injection combined with chemotherapy in colorectal cancer treatment","volume":"149","author":"Gao","year":"2023","journal-title":"J\u00a0Cancer Res Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1634688\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T05:33:03Z","timestamp":1758605583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1634688\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":175,"alternative-id":["10.3389\/fimmu.2025.1634688"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1634688","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"article-number":"1634688"}}